Barclays’s Aprea Therapeutics APRE Stock Holding History

Barclays’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$379	Buy	+473	New	+$395	﹤0.01%	5045

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's APRE Position: Q2 2026 in Review

Barclays opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 473 shares worth $379. The stake represents ﹤0.01% of the portfolio and ranks #5045 among its holdings.

28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Barclays held 473 shares of Aprea Therapeutics worth $379 as of Q2 2026.
Aprea Therapeutics was a new Barclays position in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5045 holding.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.